Eddie Pharmaceuticals: The first subject successfully enrolled in the Phase III clinical trial of ACC017 tablets.

Eddie Pharmaceuticals announced that its independently developed anti-HIV drug ACC017 tablets are undergoing a Phase III study to evaluate the effectiveness and safety in treatment-naive adults with HIV-1. The study is a multicenter, randomized, double-blind, double-dummy, multiple-dose, raltegravir sodium tablet-controlled trial. The first subject was successfully enrolled on November 7, 2025.